{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:27:42Z","timestamp":1749655662837},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.taap.2024.116912","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T07:50:57Z","timestamp":1711093857000},"page":"116912","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome"],"prefix":"10.1016","volume":"485","author":[{"given":"Mikito","family":"Hirakata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emi","family":"Tomikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chizuka","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rieko","family":"Shimozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakatsu","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoichi","family":"Itaba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Munakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiyu","family":"Oshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2024.116912_bb0005","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1124\/jpet.103.053413","article-title":"Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity","volume":"306","author":"Charrois","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.taap.2024.116912_bb0010","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13054-017-1645-x","article-title":"Anti-inflammatory properties of anesthetic agents","volume":"21","author":"Cruz","year":"2017","journal-title":"Crit. Care"},{"key":"10.1016\/j.taap.2024.116912_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2017.05.031","article-title":"Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: a single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate","volume":"106","author":"Etrych","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.taap.2024.116912_bb0020","unstructured":"Fuji Pharma Co., Ltd., 2022. Drug interview form. DOXIL\u00ae injection. (in Japanese) (accessed 11 December 2023) https:\/\/www.fuji-pharma.jp\/docs\/429\/interview_429.pdf."},{"key":"10.1016\/j.taap.2024.116912_bb0025","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1097\/NCC.0000000000000402","article-title":"The development of a nurse-led internet-based learning and self-care program for cancer patients with symptoms of anxiety and depression-a part of U-CARE","volume":"40","author":"Hauffman","year":"2017","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.taap.2024.116912_bb0030","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.0022-202X.2005.23787.x","article-title":"A guide to assessing damage response pathways of the hair follicle: lessons from cyclophosphamide-induced alopecia in mice","volume":"125","author":"Hendrix","year":"2019","journal-title":"J. Invest. Dermatol."},{"issue":"Suppl. 4","key":"10.1016\/j.taap.2024.116912_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199700544-00003","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortob\u00e1gyi","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.taap.2024.116912_bb0040","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2147\/IJN.S280187","article-title":"Reactive oxygen species-mediated inflammation and apoptosis in hand-foot syndrome induced by PEGylated liposomal doxorubicin","volume":"16","author":"Hu","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.taap.2024.116912_bb0045","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"Jacobi","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2024.116912_bb0050","article-title":"Prescribing information","author":"Janssen Products","year":"2019","journal-title":"DOXIL"},{"key":"10.1016\/j.taap.2024.116912_bb0055","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol. Rev."},{"key":"10.1016\/j.taap.2024.116912_bb0060","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1021\/acsnano.2c00423","article-title":"PEGylated liposomes accumulate in the areas relevant to skin toxicities via passive extravasation across \u201cleaky\u201d endothelium","volume":"16","author":"Li","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.taap.2024.116912_bb0065","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome)","volume":"18","author":"Lorusso","year":"2007","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2024.116912_bb0070","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/archderm.136.12.1475","article-title":"Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin","volume":"136","author":"Lotem","year":"2000","journal-title":"Arch. Dermatol."},{"issue":"12 Pt 1","key":"10.1016\/j.taap.2024.116912_bb0075","first-page":"6387","article-title":"A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs","volume":"46","author":"Matsumura","year":"1986","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2024.116912_bb0080","author":"Meiji Seika Pharma Co., Ltd"},{"key":"10.1016\/j.taap.2024.116912_bb0085","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jconrel.2013.11.011","article-title":"Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage","volume":"174","author":"Nakamura","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2024.116912_bb0090","article-title":"Method for evaluating degree of purity of pharmaceutical substance contained in composite body, and method for producing composite body","author":"Okano","year":"2021","journal-title":"WO2022\/025228"},{"key":"10.1016\/j.taap.2024.116912_bb0095","first-page":"719","article-title":"Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine a, and modulation by dexamethasone","volume":"144","author":"Paus","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2024.116912_bb0105","unstructured":"Sandoz, K.K., 2022. Drug interview form. ADRIACIN\u00ae injection. (in Japanese (accessed 11 December 2023)) https:\/\/prod.sandoz.jp\/sites\/www.sandoz.jp\/files\/adriacin_4621_interview_02.pdf."},{"key":"10.1016\/j.taap.2024.116912_bb0100","article-title":"Prescribing information","author":"Pfizer Inc","year":"2020","journal-title":"Doxorubicin Hydrochloride"},{"key":"10.1016\/j.taap.2024.116912_bb0110","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.taap.2024.116912_bb0115","article-title":"Research of side effects in anti-cancer agents: hand-foot syndrome","volume":"48","author":"Takano-Mochizuki","year":"2021","journal-title":"Ann. Meet. Japan. Soc. Toxicol."},{"issue":"10","key":"10.1016\/j.taap.2024.116912_bb0120","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.7150\/jca.31059","article-title":"Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy","volume":"2019","author":"Urakawa","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.taap.2024.116912_bb0125","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer Centre","volume":"11","author":"Webster-Gandy","year":"2007","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.taap.2024.116912_bb0130","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.gendis.2022.10.004","article-title":"DNA damage-mediated cellular senescence promotes hand-foot syndrome that can be relieved by thymidine prodrug","volume":"10","author":"Yang","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.taap.2024.116912_bb0135","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5694\/mja16.00947","article-title":"Supportive care of women with breast cancer: key concerns and practical solutions","volume":"205","author":"Zdenkowski","year":"2016","journal-title":"Med. J. Aust."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001108?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X24001108?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T12:33:26Z","timestamp":1713962006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X24001108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S0041008X24001108"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2024.116912","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2024.116912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116912"}}